Skip to content

Clinical trials

Smoldering Multiple Myeloma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Smoldering Multiple Myeloma Clear all

99 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20043
20072
20081
20095
20105
20114
20122
20133
20143
20154
20165
20176
20186
20197
20203
20217
20227
20239
20247
20254
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting28
Completed26
Active, not recruiting20
Terminated13
Withdrawn5
Not yet recruiting3
Unknown status3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Dana-Farber Cancer Institute10
National Cancer Institute (NCI)7
M.D. Anderson Cancer Center5
City of Hope Medical Center4
Janssen Research & Development, LLC4
Memorial Sloan Kettering Cancer Center3
Regeneron Pharmaceuticals3
University of Rochester3
Case Comprehensive Cancer Center2
European Myeloma Network B.V.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Smoldering Multiple Myeloma99
Multiple Myeloma46
Monoclonal Gammopathy of Undetermined Significance34
Neoplasms, Plasma Cell14
Immunoglobulin Light-chain Amyloidosis5
Waldenstrom Macroglobulinemia4
Amyloidosis3
Leukemia, Lymphocytic, Chronic, B-Cell3
Leukemia, Plasma Cell3
Paraproteinemias3

Trials

Showing 26 to 50 of 99. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.